Aptevo Therapeutics has begun dosing patients in a Phase ll clinical trial of monospecific antibody otlertuzumab to treat peripheral T-cell lymphoma (PTCL).

The open-label, proof-of-concept trial seeks to evaluate the safety and efficacy of otlertuzumab in combination with bendamustine in patients with relapsed or refractory PTCL.

The trial’s primary endpoint is response rate, evaluable by the 2017 International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). It aims to enrol up to 24 patients.

Aptevo Therapeutics senior vice-president and chief medical officer Scott Stromatt said: “Clinical proof-of-concept data from a randomised Phase ll study demonstrated the efficacy and tolerability of otlertuzumab with bendamustine in relapsed chronic lymphocytic lymphoma (CLL).

“In this study, there was a significant increase in median progression-free survival, from approximately ten to 16 months.”

“In this study, there was a significant increase in median progression-free survival, from approximately ten to 16 months in patients receiving the combination of otlertuzumab and bendamustine.

“We were intrigued by recent reports in the literature showing that CD37 appears to be overexpressed in various T-cell lymphomas, suggesting a potential role for otlertuzumab in the treatment of T-cell malignancies.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aptevo further expects that successful completion of the Phase ll trial could open up a new market opportunity for otlertuzumab in treating T-cell malignancies.

Otlertuzumab is a monospecific antibody targeting CD37 and was developed on Aptevo’s ADAPTIR modular protein therapeutic platform.